TOP-5 Price Targets of Analysts on 19.05.26

Ionis Pharmaceuticals [US4622221004] Citigroup starts coverage with a Top-Pick rating and a price target of 115 USD (58% upside potential) At the core of the positive investment thesis is the drug Tryngolza, an RNA-based therapy for lowering triglycerides, which is currently expanding from a rare indication (FCS) into the much larger target group of severe hypertriglyceridemia. Citigroup argues that the market potential is underestimated, with peak sales of over 3.5 billion USD possible—driven by strong Phase 3 data with significant effects...